Cholic Acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice

被引:12
|
作者
Pan, Xian [2 ]
Kent, Rebecca [2 ]
Won, Kyoung-Jae [1 ]
Jeong, Hyunyoung [1 ,2 ]
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice, 900 South Ashland Ave,MC 870, Chicago, IL 60607 USA
[2] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, 900 South Ashland Ave,MC 870, Chicago, IL 60607 USA
基金
美国国家卫生研究院;
关键词
SMALL HETERODIMER PARTNER; BACTERIAL TRANSLOCATION; INDUCED CHOLESTASIS; IN-VIVO; BILE; LIVER; SHP; METABOLISM; REPRESSION; BIOSYNTHESIS;
D O I
10.1124/dmd.116.074013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2D6 (CYP2D6) is a major drug-metabolizing enzyme, but the factors governing transcriptional regulation of its expression remain poorly understood. Based on previous reports of small heterodimer partner (SHP) playing an important role as a transcriptional repressor of CYP2D6 expression, here we investigated how a known upstream regulator of SHP expression, namely cholestasis triggered by cholic acid (CA) feeding in mice, can lead to altered CYP2D6 expression. To this end, CYP2D6-humanized (Tg-CYP2D6) mice were fed with a CA-supplemented or control diet for 14 days, and hepatic expression of multiple genes was examined. Unexpectedly, CA feeding led to insignificant changes in SHP mRNA but also to significant (2.8-fold) decreases in SHP protein levels. In silico analysis of the SHP gene regulatory region revealed a putative binding site for a microRNA, miR-142-3p. Results from luciferase reporter assays suggest that miR-142-3p targets the SHP gene. Hepatic expression of miR-142-3p was significantly increased in CA-fed mice (similar to 5-fold), suggesting a potential role of miR-142-3p in the regulation of SHP expression in cholestasis. The decreased SHP protein levels were accompanied by increased expression and activity of CYP2D6 in the liver of CA-fed mice. These results suggest potential roles of differential hepatic levels of bile acids in the transcriptional regulation of CYP2D6 expression.
引用
收藏
页码:346 / 352
页数:7
相关论文
共 50 条
  • [21] Transcriptional Regulation of CYP2D6 Expression
    Pan, Xian
    Ning, Miaoran
    Jeong, Hyunyoung
    [J]. DRUG METABOLISM AND DISPOSITION, 2017, 45 (01) : 42 - 48
  • [22] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    [J]. Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [23] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
  • [24] The CYP2D6 humanized mouse:: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse
    Corchero, J
    Granvil, CP
    Akiyama, TE
    Hayhurst, GP
    Pimprale, S
    Feigenbaum, L
    Idle, JR
    Gonzalez, FJ
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (06) : 1260 - 1267
  • [25] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [26] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [27] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [28] CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity
    Wang, Danxin
    Poi, Ming J.
    Sun, Xiaochun
    Gaedigk, Andrea
    Leeder, J. Steven
    Sadee, Wolfgang
    [J]. FASEB JOURNAL, 2013, 27
  • [29] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    [J]. DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [30] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S